Q-omics provides the consensus-scored C12orf45 profile across patient tissues and cancer cell-line models. C12orf45 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C12orf45 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, C12orf45 RNA expression shows 18,946 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where C12orf45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C12orf45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C12orf45 survival associations across molecular data types. C12orf45 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C12orf45 RNA expression–survival associations across cancer types. High C12orf45 expression shows unfavorable associations in KIRC, KICH, ACC, KIRP, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C12orf45 RNA expression.
This table summarizes C12orf45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C12orf45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C12orf45 shows higher tumor expression in KIRC, BLCA, KIRP, LIHC, COAD and LUAD. The KIRC box plot shows higher C12orf45 RNA expression in tumor versus normal tissue (log2 FC = +0.898, t-test p < 0.001).
This table shows molecular features associated with C12orf45 in patient tissues and cancer cell lines. In patient samples, C12orf45 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C12orf45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
